Amneal Pharmaceuticals to Acquire Cumberland Pharmaceuticals
Ticker: CPIX · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1087294
Sentiment: neutral
Topics: acquisition, merger
TL;DR
Amneal is buying Cumberland Pharmaceuticals, deal expected to close Q1 2025.
AI Summary
Cumberland Pharmaceuticals Inc. announced on November 6, 2024, that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals LLC. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition will expand Amneal's portfolio and market presence.
Why It Matters
This acquisition signifies consolidation within the pharmaceutical industry, potentially impacting market competition and the availability of Cumberland's products.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until completion.
Key Players & Entities
- Cumberland Pharmaceuticals Inc. (company) — Registrant
- Amneal Pharmaceuticals LLC (company) — Acquiring entity
- November 6, 2024 (date) — Date of agreement
- first quarter of 2025 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Cumberland Pharmaceuticals Inc. has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals LLC.
Who is acquiring Cumberland Pharmaceuticals?
Amneal Pharmaceuticals LLC is acquiring Cumberland Pharmaceuticals.
When is the acquisition expected to be completed?
The transaction is expected to close in the first quarter of 2025.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the date of the report for this filing?
The date of the report is November 11, 2024, with the earliest event reported on November 6, 2024.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-11-12 06:55:49
Filing Documents
- cpix-20241106.htm (8-K) — 27KB
- dmd-orphandrugrarediseased.htm (EX-99.1) — 22KB
- image_0a.jpg (GRAPHIC) — 24KB
- 0001628280-24-046827.txt ( ) — 209KB
- cpix-20241106.xsd (EX-101.SCH) — 2KB
- cpix-20241106_lab.xml (EX-101.LAB) — 21KB
- cpix-20241106_pre.xml (EX-101.PRE) — 12KB
- cpix-20241106_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On November 6, 2024, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the U. S. Food and Drug Administration ("FDA") granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). Cumberland is completing the FIGHT DMD trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year. A copy of the release is furnished as Exhibit 99.1 . Exhibit No. Description 99.1 Press release dated November 6 , 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: November 11, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer